Menu
Content/Inhalt
Home
|
Careers
|
Contact us
Search
Welcome
History
Social responsibility
Our companies
Debiopharm Group
Debiopharm S.A.
Debio R.P. S.A.
Debioclinic S.A.
Debiovision Inc.
Debioinnovation S.A.
Business Model
Strengths
Development capabilites
Preclinical
Clinical
Manufacturing
Regulatory
Innovative drug delivery and formulation
Partnering
Licensing-in
Licensing-out
Partners
Pipeline
Commercial Products
Eloxatin®
Decapeptyl®
News & Events
Press Releases
Awards
Publications
Conferences
News
20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions
Home
Pipeline
Other News
Filter
Order
Title asc
Title desc
Ordering
Display #
5
10
15
20
25
30
50
Item Title
Japanese Cancer Association and Debiopharm Honour Japanese Research - Professors Ichijo and Mano receive 2008 JCA-Mauvernay Award
Debiopharm investit pour les médicaments innovants de demain - Inauguration de Campus "après-demain", son site de développement et de production
Doctor Manel Esteller Receives the Debiopharm Life Sciences Award For his Outstanding Research in Epigenetic Oncology
Le "Prix Debiopharm/Valais pour les Sciences de la Vie" honore un chimiste valaisan pour son procédé électrochimique novateur
Debiopharm and Airmid Sign Option and License Agreement for the Development of Debio 0824, an ShK Peptide for Autoimmune Disorders
< Prev
1
2
3
4
5
6
7
8
9
10
Next >
Results 1 - 5 of 47
Debio 0827
( 1 items )
Debio 0826
( 1 items )
Triptorelin – Trelstar® – Decapeptyl® - Pamorelin®
( 10 items )
Debio 8609 Sanvar®
( 13 items )
Debio 025
( 5 items )
Debio 9902 - ZT-1
( 9 items )
Debio 0614 (istaroxime)
( 2 items )
Debio 0507
( 3 items )
Debio 0719
( 1 items )
Debio 0617
( 2 items )
Oxaliplatin – Eloxatin® – Elplat®
( 10 items )
Moapar® - Salvacyl®
( 3 items )